CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 61 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-16 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | −13,884 | $2.69 | $37K | 272,252 |
| 2025-06-16 | McCarthy Sean A. CEO | Sale | −55,511 | $2.69 | $149K | 1,089,684 |
| 2025-06-13 | Ogden Christopher Chief Financial Officer | Sale | −1,641 | $2.95 | $5K | 199,385 |
| 2025-06-13 | Ogden Christopher Chief Financial Officer | Option exercise | +37,500 | 236,885 | ||
| 2025-06-13 | Ogden Christopher Chief Financial Officer | Option exercise · Performance Stock Units | −37,500 | 0 | ||
| 2025-06-13 | BELVIN MARCIA SVP, Chief Scientific Officer | Option exercise | +37,500 | 286,136 | ||
| 2025-06-13 | BELVIN MARCIA SVP, Chief Scientific Officer | Option exercise · Performance Stock Units | −37,500 | 0 | ||
| 2025-06-13 | McCarthy Sean A. CEO | Option exercise | +150,000 | 1,145,195 | ||
| 2025-06-13 | McCarthy Sean A. CEO | Option exercise · Performance Stock Units | −150,000 | 0 | ||
| 2025-06-11 | Su Zhen Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Young Matthew P. Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Mohindru Mani Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Meyers James R Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Jones Elaine V Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Gilbert Halley E Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-06-11 | Ashworth Alan Director | Grant or award · Stock Option (Right to Buy) | +38,000 | 38,000 | ||
| 2025-03-18 | McCarthy Sean A. CEO | Sale | −37,656 | $0.60 | $23K | 995,195 |
| 2025-03-18 | Ogden Christopher Chief Financial Officer | Sale | −8,551 | $0.60 | $5K | 201,026 |
| 2025-03-18 | Chu Yu-Waye Chief Medical Officer | Sale | −4,025 | $0.60 | $2K | 135,725 |
| 2025-03-18 | ROWLAND LLOYD A General Counsel | Sale | −10,203 | $0.60 | $6K | 120,594 |
Page 3 of 27 · 529 trades